Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: lapatinib
Drug: carboplatin
Drug: paclitaxel
Drug: trastuzumab

First Posted Date: 2006-08-23

Last Posted Date: 2020-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT00367471

Locations: 🇺🇸
Novartis Investigative Site, Greensboro, North Carolina, United States

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Phase 2

Completed

Conditions: Neoplasm, Unknown Primary

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: bevacizumab
Drug: erlotinib

First Posted Date: 2006-08-04

Last Posted Date: 2013-12-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 60

Registration Number: NCT00360360

Locations: 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States

and more 6 locations

Trial of PTK787/ZK 222584 Plus Paclitaxel

Phase 1

Terminated

Conditions: Metastatic Non-hematologic Malignancies

Interventions: Drug: PTK787/ZK 222584
Drug: paclitaxel

First Posted Date: 2006-07-31

Last Posted Date: 2022-04-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 7

Registration Number: NCT00358163

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Phase 2

Terminated

Conditions: Breast Tumors
Breast Cancer
Locally Recurrent and Metastatic Breast Cancer
Breast Neoplasms

Interventions: Drug: AMG 706 placebo
Drug: AMG 706
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2006-07-26

Last Posted Date: 2015-10-15

Lead Sponsor: Amgen

Target Recruit Count: 282

Registration Number: NCT00356681

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Phase 1

Completed

Conditions: Neutropenia
Infectious Disorder
Stage IV Ovarian Cancer
Fallopian Tube Carcinoma
Ovarian Carcinosarcoma
Primary Peritoneal Carcinoma
Stage III Ovarian Cancer

Interventions: Procedure: Adjuvant Therapy
Drug: Carboplatin
Drug: Paclitaxel
Biological: Pegfilgrastim

First Posted Date: 2006-07-14

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 43

Registration Number: NCT00352300

Locations: 🇺🇸
Cooper Hospital University Medical Center, Camden, New Jersey, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
Lake University Ireland Cancer Center, Mentor, Ohio, United States

and more 8 locations

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Phase 2

Completed

Conditions: Urologic Neoplasm

Interventions: Drug: Cetuximab
Drug: Paclitaxel

First Posted Date: 2006-07-10

Last Posted Date: 2017-03-31

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 41

Registration Number: NCT00350025

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Paclitaxel
Drug: NOV-002
Drug: Carboplatin

First Posted Date: 2006-07-04

Last Posted Date: 2022-07-25

Lead Sponsor: Cellectar Biosciences, Inc.

Target Recruit Count: 903

Registration Number: NCT00347412

Locations: 🇵🇱
Oddzial Chemioterapii Zaklad Opieki Zdrowotnej MSWiA, Olsztyn, Poland
🇵🇱
Oddzial Gruzlicy I Chorob Pluc I P, Prabuty, Poland
🇷🇴
Institute of Oncology, Department of Medical Oncology II, Bucharest, Romania

and more 72 locations

Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Paclitaxel

First Posted Date: 2006-06-27

Last Posted Date: 2009-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 53

Registration Number: NCT00344552

Locations: 🇯🇵
Local Institution, Saitama, Japan

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Cetuximab
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2006-06-22

Last Posted Date: 2011-06-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 121

Registration Number: NCT00343291

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tacoma, Washington, United States

A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Paclitaxel
Drug: cisplatin

First Posted Date: 2006-06-16

Last Posted Date: 2010-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT00337532

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of
🇰🇷
Local Insitution, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy